0000905718-21-000760.txt : 20210607
0000905718-21-000760.hdr.sgml : 20210607
20210607085345
ACCESSION NUMBER: 0000905718-21-000760
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210603
FILED AS OF DATE: 20210607
DATE AS OF CHANGE: 20210607
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Muralidhar Bali
CENTRAL INDEX KEY: 0001784138
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40315
FILM NUMBER: 21998379
MAIL ADDRESS:
STREET 1: C/O EXICURE, INC.
STREET 2: 8045 LAMON AVENUE, SUITE 410
CITY: SKOKIE
STATE: IL
ZIP: 60077
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Reneo Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001637715
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 472309515
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 12230 EL CAMINO REAL
STREET 2: SUITE 230
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: (858) 283-0280
MAIL ADDRESS:
STREET 1: 12230 EL CAMINO REAL
STREET 2: SUITE 230
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
4
1
reneo_fm4jun32021.xml
X0306
4
2021-06-03
0
0001637715
Reneo Pharmaceuticals, Inc.
RPHM
0001784138
Muralidhar Bali
C/O RENEO PHARMACEUTICALS, INC.
12230 EL CAMINO REAL, SUITE 230
SAN DIEGO
CA
92130
1
0
0
0
Common Stock
2021-06-03
4
P
0
12100
9.2515
A
1877375
I
By Abingworth Bioventures 8 LP
Common Stock
2021-06-04
4
P
0
257
9.4242
A
1877632
I
By Abingworth Bioventures 8 LP
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.08 to $9.50 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.30 to $9.50 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.
The shares are held by Abingworth Bioventures 8 LP ("Abingworth 8"). Abingworth Bioventures 8 GP LP serves as the general partner of Abingworth 8. Abingworth General Partner 8 LLP, (together with Abingworth Bioventures 8 GP LP, the "General Partners"), serves as the general partner of Abingworth Bioventures 8 GP LP. Abingworth 8 (acting by its general partner Abingworth Bioventures 8 GP LP, acting by its general partner Abingworth General Partner 8 LLP) has delegated to Abingworth LLP all investment and dispositive power over the securities held by Abingworth 8. The Reporting Person, a Director of the Issuer, is a member of an investment committee of Abingworth 8 which approves investment and voting decisions by majority vote and no individual member has the sole control or voting power over the securities held by Abingworth 8.
Each of Abingworth 8, Abingworth LLP, the General Partners, the Reporting Person and each member of the Investment Committee disclaims beneficial ownership of the common stock held by Abingworth 8, except to the extent of their pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
/s/ John Heard, as attorney-in-fact
2021-06-07